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Pacemaking activity in adult substantia nigra (SN) dopamine neurons relies on L-type Ca2+ channels,
but a surprising study in Nature by Chan et al. demonstrates that blockade of these channels by
dihydropyridines re-establishes the pacemaking driven by sodium and HCN channels found in
juvenile SN. This shift protects SN neurons in chemical models of Parkinson’s disease (PD), suggest-
ing that elevated intracellular Ca2+ participates in SN cell loss and that dihydropyridines may provide
therapy in PD.Parkinson’s disease (PD) is diagnosed
by a set of voluntarymotor control dys-
functions known as ‘‘parkinsonism’’
that are due to the death of substantia
nigra (SN) dopamine (DA) neurons and
can be alleviated by DA replacement
therapy using L-DOPA (Dauer and
Przedborski, 2003; Sulzer, 2007). A
major question is why certain neurons
are targeted, and particularly why SN
neurons die while neighboring mid-
brain DA neurons of the ventral teg-
mental area (VTA) are relatively spared
(Damier et al., 1999).
A clue is provided by the unusual
physiological properties of adult ven-
tralmidbrainDAneurons,which exhibit
pacemaker activity in the absence of
excitatory input (Grace and Onn,
1989), a feature widely suspected to
underlie normal voluntary motor con-
trol, although there is at present little
proof of that conjecture. Pacemaking8 Neuron 55, July 5, 2007 ª2007 Elseviein SNDAneurons depends on somato-
dendritic L-type channel-driven Ca2+
currents (Nedergaard et al., 1993) and
to some extent or in some subpopu-
lations on hyperpolarization-activated
and cyclic nucleotide-gated cation
(HCN) channels (Mercuri et al., 1995;
Neuhoff et al., 2002) together with
Ca2+-activated SK K+ channels that
produce an afterhyperpolarization
that delays return to threshold (Neder-
gaard et al., 1993).
The Ca2+ flux that underlies SN
pacemaking is large, and midbrain DA
neurons are to date unique in possess-
ing a greater interspike calcium current
than sodium current (Puopolo et al.,
2007). Together with high Ca2+ flux
that occurs during their relatively wide
action potentials and presumed addi-
tional current when the neurons burst
fire with excitatory input (Kuznetsov
et al., 2006), normal SN neuron activityr Inc.seems to entail unusually high Ca2+
entry.
In a new study published in Nature,
James Surmeier’s group at Northwest-
ern University reports several surpris-
ing features of this pacemaking activity
(Chanet al., 2007). First, pacemaking is
already present in newborn mouse SN
neurons but is driven by sodium chan-
nels in conjunctionwithHCNchannels.
Then, during the second week follow-
ing birth, there is a gradual switch as
Cav1.3 current increases, perhaps as
the voltage dependence of HCN chan-
nels is shifted toward more negative
membrane potentials, essentially tak-
ing HCN channels ‘‘off-line.’’ The
development of SN Ca2+-driven pace-
making occurs in tandem with an in-
creased expression of slowly inacti-
vating somatodendritic L-type Ca2+
channels that drive the neurons into
oscillations, due to the presence of
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PreviewsCav1.3 a subunits, which open in a rel-
atively hyperpolarized subthreshold
range (50 mV). In support of these
new observations, knockout mice that
don’t express the Cav1.3 a subunit of
L-type Ca2+ channels continue to show
SN pacemaking driven by the sodium/
HCN currents throughout their lives.
While normal adult VTA neurons also
have Cav1.3 channels, they continue
for unknown reasons to exhibit pace-
making driven by sodium channels.
L-type Ca2+ channels have been
pharmacological targets for more
than three decades because they reg-
ulate the pacemaking currents under-
lying heart muscle contraction. Dihy-
dropyridines including nimodipine and
isradipine have been prescribed to
millions of patients for hypertension
treatment. These drugs possess an
unusual feature in that they show a
higher apparent affinity with depolar-
ization (Sanguinetti and Kass, 1984)
and are thus particularly efficacious in
heart and smooth muscle, as these tis-
sues maintain a relatively high resting
potential.
The Surmeier group found that in
ventral midbrain slices from normal
adult mice, as expected, dihyropyri-
dines halted SN pacemaking. Amaz-
ingly, however, pacemaking returned
to SN neurons very rapidly, within 2
or 4 hr of exposure, again driven by
sodium/HCN currents.
The remarkable compensatory
switch in the ionic basis of pacemaker
activity by SN neurons following dihy-
dropyridine exposure suggested that
dihyrdopyridine treatment might help
prevent nigral cell loss in PD. The field
of PD research, however, still lacks
a mouse line that expresses a familial
PD mutation that results in selective
PD-like SN neuronal death, and so
the investigators tested effects of isra-
dipine on well-established chemical
toxin models that selectively kill SN
neurons: MPTP, 6-hydroxy-DA, and
the mitochondrial complex I inhibitor,
rotenone (Dauer and Przedborski,
2003). The dihydropyridines, particu-
larly isradapine, which has a compara-
tively high affinity forCav1.3, effectively
blocked the chemically induced neuro-
degeneration, and a retrospective
search of the epidemiological literaturerevealed an observation that patients
taking dihydropyridines had substan-
tially lower than usual incidence of PD.
How do these results contribute to
understanding neurodegeneration in
PD? All humans presumably have
Cav1.3 L-type Ca
2+ channels in SN
DA neurons, and yet the lifetime inci-
dence of PD is at most 2% (Sulzer,
2007). Other neurons, in particular co-
chlear hair cells, maintain L-type chan-
nel currents that control synaptic exo-
cytosis (Striessnig et al., 2006) but are
not known to be damaged in PD. The
results, nevertheless, fit with the idea
that PD, which exhibits low genetic
penetrance, requires ‘‘multiple hits’’
(Sulzer, 2007), unlike some other mo-
tor disorders that result from dysfunc-
tion of a single enzyme. High cytosolic
Ca2+ is well known to induce oxidative
stress and excitotoxicity and has long
been suspected to play a role in PD
(Beal, 1998), although there has been
little direct evidence. Ventral midbrain
DA neurons have among the most
extensive neuritic arborization in the
CNS, and are likely to express L-type
channels in SN dendrites, which con-
tain DA secretory vesicles and mito-
chondria and presumably require sub-
stantial energy supplies. It has long
been suspected that PD neurodegen-
eration begins in neurites, and perhaps
high cytosolic Ca2+ can initiate oxida-
tive stress and excitotoxicity in den-
dritic spines.
While the new study does not tie to-
gether the role of mutant genes that
cause familial PDwith high Ca2+ levels,
mitochondria buffer cytosolic Ca2+,
which may link SN death to several
genetic mutations that may be asso-
ciated with mitochondria and are iden-
tified to cause familial PD (Sulzer,
2007), including PINK1, DJ-1, and
LRRK2. The new results may also
help explain one of the long-noted
differences between SN and VTA neu-
ron loss in PD (Damier et al., 1999) and
in themouseMPTPmodel (Liang et al.,
1996): most VTA neurons and a subset
of SN neurons that are spared in PD
and with MPTP express substantially
higher levels of calbindin, a protein
that additionally buffers cytosolicCa2+.
More important immediately, how-
ever, may be the implication that dihy-Neudropyridines could attenuate neurode-
generation in PD. This objective may
not be straightforward: these drugs
tend to have a higher affinity for
Cav1.2 L-type channels than Cav1.3
channels that underlie SN pacemak-
ing. The concentration of isradipine
used to temporarily halt pacemaking
and prevent toxin-induced neurode-
generation in the study is high, and
while many hypertensive patients take
dihydropyridines with no ill effects,
the drugs will cause hypotension in
otherwise normal patients: it is pos-
sible that doses lower than those used
in the study will be efficacious. A note
of caution is struck from the observa-
tion that mice that lack the Cav1.3 sub-
unit are deaf (Striessnig et al., 2006), as
might be expected from the above-
mentioned roles of L-type Ca2+ chan-
nels in cochlear hair cell activity; fortu-
nately, this has not been reported in
humans, perhaps because the voltage
dependence of the dihydropyridine
block makes them poor blockers of
channel opening driven by rapid volt-
age fluctuations but effective blockers
during the slow depolarizations associ-
ated with pacemaking. Finally, L-type
channels further appear to underlie
forms of synaptic plasticity, including
the regulation of synaptic input and
morphological changes that occur in
dendritic spines (Day et al., 2006), and
L-type channel inhibition may interfere
with these normal synaptic functions.
Sill, most neurons and smooth mus-
cle cells contain mainly the Cav1.2
a subunits, and it may be that identifi-
cation of a relatively specific Cav1.3
channel antagonist would provide
a means to turn off SN Ca2+-driven
pacemaking and return it to a normally
acting but ‘‘rejuvenated’’ sodium-
driven pacemaker, thus protecting
the SN downstream from the initial
underlying cause of PD with little dis-
turbance of other important L-type
channel-driven functions.
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